SCHEMBL2820958

SCHEMBL2820958

CCCC(=O)N[C@H](C(=O)O)[C@@H](C)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
PLA2G2A P14555 1/20 0.41
PLA2G5 P39877 1/20 0.41
CTSD P07339 1/20 0.40
PSMB5 P28074 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MME P08473 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SDCBP O00560 2/20 0.38
SDC2 P34741 2/20 0.38
NOD1 Q9Y239 1/20 0.38
CA2 P00918 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4743495 1.00 FAAH (0.42) FAAHHDAC3HDAC1HDAC2HDAC8
SCHEMBL8644196 0.89 FAAH (0.52) FAAHMEN1MAPK1KMT2APLA2G2A
SCHEMBL8644193 0.89 FAAH (0.52) FAAHMEN1MAPK1KMT2APLA2G2A
SCHEMBL9831703 0.87 FAAH (0.59) FAAHMEN1MAPK1KMT2APLA2G2A
SCHEMBL11047677 0.87 FAAH (0.59) FAAHMEN1MAPK1KMT2APLA2G2A
SCHEMBL6138003 0.87 FAAH (0.59) FAAHMEN1MAPK1KMT2APLA2G2A
SCHEMBL6256412 0.86 PLA2G2A (0.54) FAAHHDAC3HDAC1HDAC2HDAC8
SCHEMBL1734627 0.86 PLA2G2A (0.54) FAAHHDAC3HDAC1HDAC2HDAC8
SCHEMBL28220811 0.86 HDAC3 (0.43) FAAHHDAC3HDAC1HDAC2HDAC8
SCHEMBL28220813 0.86 HDAC3 (0.43) FAAHHDAC3HDAC1HDAC2HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4859653-A Use of compositions of matter containing N-acylates of alpha aminoacids for the treatment of skin MORELLE JEAN V (FR) 1989-08-22 US claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 US disclosed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 EP disclosed
CN-118488855-A Solid composition comprising peptide or protein and acylated amino acid 阿道恰公司 2024-08-13 CN disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 EP disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 EP disclosed
CN-104086633-B Short fatty acid tail polymyxin derivatives and application thereof 北方抗生素有限公司 2018-02-09 CN disclosed
CN-103379911-B PGC-1 alpha modulating peptides LIPOTEC, S.A. (ES) 2016-05-25 CN disclosed
CN-105050584-A Topical formulations of corticosteroids with enhanced bioavailability PREC DERMATOLOGY INC 2015-11-11 CN disclosed
CN-104363893-A Cyclodextrin-based microemulsions and their use for skin disorders PREC DERMATOLOGY INC 2015-02-18 CN disclosed
US-20140234903-A1 BIOSYNTHETIC GENE CLUSTER FOR THE PRODUCTION OF PEPTIDE/PROTEIN ANALOGUES ETH ZURICH (CH) 2014-08-21 US disclosed
CN-103169626-A Stabilizing method for external composition ROHTO PHARMA 2013-06-26 CN disclosed
CN-102793632-A Component for external use ROHTO PHARMA 2012-11-28 CN disclosed
EP-2242765-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF Northern Antibiotics Oy (FI) 2010-10-27 EP disclosed
WO-2009098357-A1 SHORT FATTY ACID TAIL POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS OY (FI) 2009-08-13 WO disclosed
EP-2057185-A1 POLYMYXIN DERIVATIVES AND USES THEREOF Northern Antibiotics Oy (FI) 2009-05-13 EP disclosed
WO-2008017734-A1 POLYMYXIN DERIVATIVES AND USES THEREOF NORTHERN ANTIBIOTICS OY (FI) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP FAAH 858/4885HDAC3 752/4885HDAC1 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.